title: Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr.
abstract: A lentiviral vector capable of expressing the HIV-1 vpr gene (Vpr lentiviral vector) was constructed, and its in vivo anticancer effect was determined against cutaneous tumors derived from the AT-84 oral cancer cells in immunocompetent mice. A single intratumoral injection of the Vpr lentiviral vector not only significantly reduced the primary tumor volume but also completely regressed tumors in >40% of animals. More interestingly, the mice of which the primary tumors were completely regressed by the Vpr lentiviral vector were additionally protected from a secondary challenge of AT-84 cells. These data suggest that the Vpr lentiviral vector elicits its anticancer activity in part by the activation of the immune system. The above suggestion is additionally supported by the failure of the lentiviral vector to demonstrate anticancer activity in immunocompromised nude or SCID mice. The Vpr lentiviral vector offers a powerful new strategy for cancer gene therapy and may be useful for the control of solid tumors, such as human oral squamous cell carcinomas.
authors.affiliation: School of Dentistry, Dental Research Institute, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1668, USA.
authors.forename: S
authors.initials: S
authors.lastname: Pang
authors.forename: M K
authors.initials: MK
authors.lastname: Kang
authors.forename: S
authors.initials: S
authors.lastname: Kung
authors.forename: D
authors.initials: D
authors.lastname: Yu
authors.forename: A
authors.initials: A
authors.lastname: Lee
authors.forename: B
authors.initials: B
authors.lastname: Poon
authors.forename: I S
authors.initials: IS
authors.lastname: Chen
authors.forename: B
authors.initials: B
authors.lastname: Lindemann
authors.forename: N H
authors.initials: NH
authors.lastname: Park
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000235:genetics; D002455:Cell Division / Q000235:genetics; D015870:Gene Expression; D016336:Gene Products, vpr / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D049452:Green Fluorescent Proteins; D015497:HIV-1 / Q000235:genetics; D016867:Immunocompromised Host; D016086:Lentivirus / Q000235:genetics; D008164:Luminescent Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D008819:Mice, Nude; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D054325:vpr Gene Products, Human Immunodeficiency Virus
chemical_list: D000970:Antineoplastic Agents; D016336:Gene Products, vpr; D008164:Luminescent Proteins; D011993:Recombinant Fusion Proteins; D054325:vpr Gene Products, Human Immunodeficiency Virus; D049452:Green Fluorescent Proteins